Cardiovascular events and intensity of treatment in polycythemia vera.

  title={Cardiovascular events and intensity of treatment in polycythemia vera.},
  author={Roberto Marchioli and Guido Finazzi and Giorgina Specchia and Rossella Rosaria Cacciola and Riccardo Cavazzina and Daniela Cilloni and Valerio De Stefano and Elena Elli and Alessandra Iurlo and Roberto Latagliata and Francesca Lunghi and Monia Lunghi and Rosa Maria Marfisi and Pellegrino Musto and Arianna Masciulli and Caterina Musolino and Nicola Cascavilla and Giovanni Quarta and Maria Luigia Randi and Davide Rapezzi and Marco Ruggeri and Elisa Rumi and Anna Rita Scortechini and Simone Santini and Marco Scarano and Sergio Siragusa and Antonio Spadea and Alessia Tieghi and Emanuele Angelucci and Giuseppe Visani and Alessandro Maria Vannucchi and Tiziano Barbui},
  journal={The New England journal of medicine},
  volume={368 1},
BACKGROUND Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. METHODS We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45… CONTINUE READING